Pharmacogenomics: Tailoring drug therapies for improved outcomes

While research from as far back as the 1960's indicates that genetic variations are directly responsible for different medication responses, only recently have the reduced costs of testing made the benefits of pharmacogenomics (PGx) available to many patients. While the list of clinical trials and PGx tests is continually expanding, many medications are not yet associated with clinically useful guidance.

Download White Paper

You may also like:

Blog Post

Change can mean innovation and growth. But change can also mean disruption, high costs, and breakdowns in processes. For healthcare organizations that are looking to not just survive but thrive in the new economy, we took a loo...

View Blog Post
Blog Post

To commemorate World AIDS Day, we interviewed Ross Slotten, MD, a family practitioner specializing in the care of people with HIV/AIDS in Chic...

View Blog Post
White Paper

The new health economy is here. Do you have the right knowledge resources in place? The rapid pace of innovation, the rise of consumerism, an aging population, and movement toward price transparency are placing sign...

View White Paper

Filter by Type

Sign up to receive the latest news and information!

Sign Up